Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III, Single Arm, Open Label, International, Multi Centre Study to Evaluate the Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH) on Stable Lipid Lowering Therapy

Next Previous
Trial Profile

Phase III, Single Arm, Open Label, International, Multi Centre Study to Evaluate the Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH) on Stable Lipid Lowering Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lomitapide (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Amryt Pharma

Most Recent Events

  • 08 Jul 2024 Status changed from active, no longer recruiting to completed.
  • 05 Jan 2023 Primary endpoint (Percent change in LDL-C at Week 24+/-3 days compared to Baseline) has been met as per Amryt Pharma Media Release
  • 05 Jan 2023 Results published in the Amryt Pharma Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top